Studies have failed to confirm that MMP-9 has any beneficial impact in the acute phase of stroke, where it primarily contributes to processes such as blood–brain barrier damage; indeed, it may serve as a prognostic biomarker of poor outcome. Here, MMP9 is linked to Stroke.